Metagenomic Sequencing Is Estimated To Witness High Growth Owing To Rising R&D Investments In Biomarker Discovery

Metagenomic sequencing refers to the direct sequencing of microbial communities present in diverse environmental samples without culturing. It enables detection and characterization of microbial populations in different habitats and provides insights into their genetic potential and functions. Metagenomic sequencing helps discover novel biomarkers and metabolites for various medical conditions by analyzing human microbiomes. The increasing R&D spending by pharmaceutical and biotechnology companies on biomarker identification and drug development is fueling the demand for metagenomic sequencing techniques.

The global Metagenomic Sequencing Market was valued at US$ 1.41 Bn in 2023 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030, as highlighted in a new report published by CoherentMI.

Market Opportunity:

Rising focus on biomarker discovery for personalized medicine: Biomarker identification through metagenomic sequencing of human microbiomes is expected to play a key role in development of personalized medicine. The identification of novel biomarkers can help predict disease risk, diagnose medical conditions accurately, determine appropriate treatments, and monitor treatment response for precision and personalized therapies. The growing emphasis on biomarker-driven therapeutic approaches will boost investments in metagenomic sequencing research, thereby augmenting market growth over the forecast period.

Porter's Analysis:

Threat of new entrants: The global metagenomic sequencing market requires high capital investment for research and development. This acts as a barrier for new companies to enter this market.

Bargaining power of buyers: Buyers have moderate bargaining power as there are many established players offering customized sequencing solutions and services.

Bargaining power of suppliers: Suppliers have moderate bargaining power as raw material requirements are specialized and players have alternative sourcing options.

Threat of new substitutes: There is negligible threat from substitutes as metagenomics technology is evolving but there are no perfect substitutes available yet.

Competitive rivalry: The global market is consolidated with few large players dominating the market. Intense competition exists based on technology, quality, and pricing.

SWOT Analysis:

Strengths: Emerging technology with wide scope of applications. Established players investing in R&D to develop novel tools and databases.
Weaknesses: High setup and analysis cost. Requirement of specialized skills to operate advanced instruments and interpret complex datasets.
Opportunities: Scope for customized sequencing solutions for clinical diagnosis, industrial, and environmental applications. Growth in healthcare expenditure and genome initiatives in developing nations.
Threats: Stringent regulatory compliance. Ethical concerns regarding genomic data use and storage.

Global Metagenomic Sequencing Market Segmentation:

• By Technology:
• Sequencing
• Bioinformatics
• PCR
• Microarray
• Others
• By Product:
• Instruments
• Reagents & Consumables
• Services
• Analysis Softwares
• By Application
• Drug Discovery
• Disease Diagnosis
• Environmental Remediation
• Gut Microbe Characterization
• Others
• By End User:
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Agriculture & Biofuel Companies
• Hospitals & Clinics
• Others

Key Takeaways:

The Global Metagenomic Sequencing Market Size is expected to witness high growth over the forecast period driven by increasing investments in microbiome research and expanding applications. The global Metagenomic Sequencing Market is estimated to be valued at US$ 1.41 Bn in 2023 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030.

North America currently dominates the market due to presence of major players, strong government support for genomics projects, and growing industry-academia collaborations. Europe and Asia Pacific are also lucrative markets with presence of advanced research infrastructure, growing biotechnology industry, and rising R&D expenditure.

Key players operating in the global metagenomic sequencing market are Illumina, QIAGEN, Thermo Fisher Scientific, Oxford Nanopore Technologies, BGI Group, PerkinElmer, GENEWIZ, Macrogen, Zymo Research, Diversigen, Microsynth AG, BaseClear, MR DNA (Molecular Research), Eurofins Scientific, Novogene Corporation, NuGEN Technologies, Takara Bio, Swift Biosciences, New England Biolabs, and CosmosID. Leading companies are investing in expanding sequencing capacities and launching innovative solutions to gain market share.

Explorer more information on this topic, Please visit @ https://www.marketwebjournal.com/global-metagenomic-sequencing-market-demand-and-growth-analysis/